These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 24566681)
21. Aberrant promoter methylation of p15 (INK⁴b) and p16 (INK⁴a) genes may contribute to the pathogenesis of multiple myeloma: a meta-analysis. Wang X; Zhu YB; Cui HP; Yu TT Tumour Biol; 2014 Sep; 35(9):9035-43. PubMed ID: 24908414 [TBL] [Abstract][Full Text] [Related]
22. Aberrant promoter methylation of the CHD1 gene may contribute to the pathogenesis of breast cancer: a meta-analysis. Gu X; Xue JQ; Zhu X; Ye MS; Zhang WH Tumour Biol; 2014 Sep; 35(9):9395-404. PubMed ID: 24952891 [TBL] [Abstract][Full Text] [Related]
23. RUNX3 promoter methylation correlation with pathogenesis of hepatocellular carcinoma in Asians. Lu W; Liu Y; Liu LL; Zhuang PH Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27420934 [TBL] [Abstract][Full Text] [Related]
24. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma. Zhang YJ; Ahsan H; Chen Y; Lunn RM; Wang LY; Chen SY; Lee PH; Chen CJ; Santella RM Mol Carcinog; 2002 Oct; 35(2):85-92. PubMed ID: 12325038 [TBL] [Abstract][Full Text] [Related]
25. Intensive hypermethylation of the CpG island of Ras association domain family 1A in hepatitis B virus-associated hepatocellular carcinomas. Zhong S; Yeo W; Tang MW; Wong N; Lai PB; Johnson PJ Clin Cancer Res; 2003 Aug; 9(9):3376-82. PubMed ID: 12960125 [TBL] [Abstract][Full Text] [Related]
26. Association of RASSF1A promoter methylation with lung cancer risk: a meta-analysis. Huang YZ; Wu W; Wu K; Xu XN; Tang WR Asian Pac J Cancer Prev; 2014; 15(23):10325-8. PubMed ID: 25556469 [TBL] [Abstract][Full Text] [Related]
27. Promoter hypermethylation of DNA damage response genes in hepatocellular carcinoma. Li Z; Zhang H; Yang J; Hao T; Li S Cell Biol Int; 2012 May; 36(5):427-32. PubMed ID: 21864295 [TBL] [Abstract][Full Text] [Related]
28. Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma. Schagdarsurengin U; Wilkens L; Steinemann D; Flemming P; Kreipe HH; Pfeifer GP; Schlegelberger B; Dammann R Oncogene; 2003 Mar; 22(12):1866-71. PubMed ID: 12660822 [TBL] [Abstract][Full Text] [Related]
29. Relationship between RUNX3 methylation and hepatocellular carcinoma in Asian populations: a systematic review. Lu XX; Zhu LQ; Pang F; Sun W; Ou C; Li Y; Cao J; Hu YL Genet Mol Res; 2014 Jul; 13(3):5182-9. PubMed ID: 25061743 [TBL] [Abstract][Full Text] [Related]
30. Association between Ras association domain family 1A promoter methylation and hepatocellular carcinoma: a meta-analysis. Zhao ZH; Fan YC; Yang Y; Wang K World J Gastroenterol; 2013 Nov; 19(41):7189-96. PubMed ID: 24222965 [TBL] [Abstract][Full Text] [Related]
31. Combination of LINE-1 hypomethylation and RASSF1A promoter hypermethylation in serum DNA is a non-invasion prognostic biomarker for early recurrence of hepatocellular carcinoma after curative resection. Liu ZJ; Huang Y; Wei L; He JY; Liu QY; Yu XQ; Li ZL; Zhang J; Li B; Sun CJ; Liang WB; Sun AM; Qin Y Neoplasma; 2017; 64(5):795-802. PubMed ID: 28592132 [TBL] [Abstract][Full Text] [Related]
32. Association of RASSF1A promoter methylation with gastric cancer risk: a meta-analysis. Shi DT; Han M; Gao N; Tian W; Chen W Tumour Biol; 2014 Feb; 35(2):943-8. PubMed ID: 23982879 [TBL] [Abstract][Full Text] [Related]
33. The relationship between RASSF1A gene promoter methylation and the susceptibility and prognosis of melanoma: A meta-analysis and bioinformatics. Shao C; Dai W; Li H; Tang W; Jia S; Wu X; Luo Y PLoS One; 2017; 12(2):e0171676. PubMed ID: 28207831 [TBL] [Abstract][Full Text] [Related]
34. [Aberrant methylation of multiple genes and its clinical implication in hepatocellular carcinoma]. Lou C; Yang B; Gao YT; Wang YJ; Nie FH; Yuan Q; Zhang CL; Du Z Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):831-6. PubMed ID: 19173828 [TBL] [Abstract][Full Text] [Related]
35. RASSF1A gene methylation is associated with nasopharyngeal carcinoma risk in Chinese. Wu K; Xu XN; Chen Y; Pu XL; Wang BY; Tang XD Asian Pac J Cancer Prev; 2015; 16(6):2283-7. PubMed ID: 25824751 [TBL] [Abstract][Full Text] [Related]
36. Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Zhang YJ; Wu HC; Shen J; Ahsan H; Tsai WY; Yang HI; Wang LY; Chen SY; Chen CJ; Santella RM Clin Cancer Res; 2007 Apr; 13(8):2378-84. PubMed ID: 17438096 [TBL] [Abstract][Full Text] [Related]
37. RASSF1A promoter methylation is associated with increased risk of thyroid cancer: a meta-analysis. Shou F; Xu F; Li G; Zhao Z; Mao Y; Yang F; Wang H; Guo H Onco Targets Ther; 2017; 10():247-257. PubMed ID: 28123306 [TBL] [Abstract][Full Text] [Related]
38. DNA methylation markers and serum α-fetoprotein level are prognostic factors in hepatocellular carcinoma. Lin JC; Wu YC; Wu CC; Shih PY; Wang WY; Chien YC Ann Hepatol; 2015; 14(4):494-504. PubMed ID: 26019036 [TBL] [Abstract][Full Text] [Related]
39. Associations between RASSF1A promoter methylation and NSCLC: a meta-analysis of published data. Liu WJ; Tan XH; Guo BP; Ke Q; Sun J; Cen H Asian Pac J Cancer Prev; 2013; 14(6):3719-24. PubMed ID: 23886171 [TBL] [Abstract][Full Text] [Related]
40. The relationship between RASSF1A promoter methylation and thyroid carcinoma: A meta-analysis of 14 articles and a bioinformatics of 2 databases (PRISMA). Niu H; Yang J; Yang K; Huang Y Medicine (Baltimore); 2017 Nov; 96(46):e8630. PubMed ID: 29145283 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]